Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
02.09. | Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line | 3 | FierceBiotech | ||
02.09. | Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab | 385 | AFX News | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of... ► Artikel lesen | |
ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
02.09. | Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M | 2 | Seeking Alpha | ||
02.09. | Royalty Pharma plc: Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million | 503 | GlobeNewswire (Europe) | Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab... ► Artikel lesen | |
02.09. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Zenas BioPharma reports Q2 results | 2 | Seeking Alpha | ||
12.08. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
12.08. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.08. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 137 | GlobeNewswire (Europe) | - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis... ► Artikel lesen | |
10.07. | Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target | 4 | Investing.com | ||
03.07. | Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating | 1 | Investing.com | ||
03.07. | Morgan Stanley nimmt Zenas Biopharma-Aktie mit Übergewichtung in Beobachtung auf | 18 | Investing.com Deutsch | ||
20.06. | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 175 | GlobeNewswire (Europe) | WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in... ► Artikel lesen | |
12.06. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.06. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.05. | Zenas BioPharma, Inc. GAAP EPS of -$0.80, revenue of $10M | 1 | Seeking Alpha | ||
15.05. | Zenas BioPharma May 2025 slides: key data readouts expected by year-end | 1 | Investing.com | ||
15.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.05. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AMGEN | 253,65 | -0,35 % | Amgen investiert 650 Millionen Dollar in US-Produktionsnetzwerk | Der Biotechnologiekonzern Amgen kündigt eine großangelegte Erweiterung seines US-amerikanischen Produktionsnetzwerks an. Insgesamt 650 Millionen US-Dollar fließen in den Ausbau des Standorts Juncos... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 515,60 | +0,86 % | EQS-News: Formycon AG: Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron | EQS-News: Formycon AG
/ Schlagwort(e): Markteinführung/Vereinbarung
Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 46,880 | +2,31 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism | New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 30,000 | +0,47 % | Arrowhead Pharmaceuticals vor FDA-Entscheidung: Attraktive Kaufchance? | Arrowhead Pharmaceuticals steht kurz vor entscheidenden Weichenstellungen, die den langfristigen Erfolg des Unternehmens maßgeblich beeinflussen könnten. Rückenwind gibt's aktuell durch einen starken... ► Artikel lesen | |
SWEDISH ORPHAN BIOVITRUM | 27,800 | +2,73 % | Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi | STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are... ► Artikel lesen | |
INSMED | 123,00 | -2,38 % | Insmed stock price target raised to $193 by TD Cowen on positive PAH data | ||
SCHOLAR ROCK | 29,200 | -1,35 % | Scholar Rock: Zulassung vertagt? Egal - die Aktie rockt! | Unglaublich, aber wahr: Die Aktie der Biotech-Gesellschaft Scholar Rock ist nach dem abgelehnten Zulassungsantrag für Apitegromab zur Behandlung der spinalen Muskelatrophie nur kurz abgetaucht. Seitdem... ► Artikel lesen | |
PROQR THERAPEUTICS | 1,904 | +3,59 % | ProQR Therapeutics N.V.: ProQR Announces Second Quarter 2025 Operating and Financial Results | Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall... ► Artikel lesen | |
CRINETICS PHARMACEUTICALS | 35,800 | +0,56 % | Crinetics Pharmaceuticals: Potenzial nach FDA-Zulassung? | Crinetics Pharmaceuticals hat in den vergangenen Monaten bedeutende Fortschritte erzielt. Allen voran die erfolgreiche US-Zulassung von Paltusotin zur Behandlung von Akromegalie Ende vergangener Woche... ► Artikel lesen | |
VENTYX BIOSCIENCES | 3,590 | 0,00 % | Ventyx Biosciences: Clear Street startet Coverage mit Kaufempfehlung | ||
THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.09.2025 | Das Instrument 4D7 JP3486800000 DAITO TR. CONSTR. EQUITY wird cum Kapitalmassnahme gehandelt am 26.09.2025 und ex Kapitalmassnahme am 29.09.2025 The instrument 4D7 JP3486800000 DAITO TR. CONSTR. EQUITY... ► Artikel lesen | |
ENSYSCE BIOSCIENCES | 2,450 | 0,00 % | Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium | ~ Experts Spotlight TAAP and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 38,640 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
TEVOGEN BIO | 0,650 | -3,85 % | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
TOURMALINE BIO | 47,860 | 0,00 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen |